Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.97 |
| ▸ | MAPT | P10636 | 7/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | MPI | P34949 | 1/20 | 0.80 |
| ▸ | FBP1 | P09467 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2762927 | 0.99 | ADORA1 (0.95) | ADORA1MAPTKDM4EALDH1A1MPI | |
| SCHEMBL12797292 | 0.92 | ADORA1 (0.83) | ADORA1MAPTKDM4EALDH1A1MPI | |
| SCHEMBL6885965 | 0.89 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1MPI | |
| Iodide SCHEMBL3994593 | 0.86 | ADORA1 (1.00) | ADORA1MAPTKDM4EALDH1A1MPI | |
| Iodide SCHEMBL3991649 | 0.82 | ADORA1 (0.72) | ADORA1MAPTKDM4EALDH1A1MPI | |
| SCHEMBL12797289 | 0.81 | MAPT (0.85) | ADORA1MAPTKDM4EALDH1A1MPI | |
| SCHEMBL20641264 | 0.80 | FBP1 (0.66) | ADORA1MAPTKDM4EALDH1A1MPI | |
| Iodide SCHEMBL3994783 | 0.80 | ADORA1 (0.69) | ADORA1MAPTKDM4EALDH1A1MPI | |
| SCHEMBL2762751 | 0.80 | KDM4E (0.67) | ADORA1MAPTKDM4EALDH1A1MPI | |
| Iodide SCHEMBL3994807 | 0.80 | ADORA1 (0.67) | ADORA1MAPTKDM4EALDH1A1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869360-B | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3652164-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-110869360-A | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2020-03-06 | — | — | CN | disclosed |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019014300-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | METAP1, METAP2, ENPEP | ADORA1 2941/4885MAPT 1551/4885KDM4E 3317/4885 |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | ADORA1 2686/4885MAPT 121/4885KDM4E 1159/4885 |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | MYLK, ROCK1, ROCK2 | ADORA1 2686/4885MAPT 121/4885KDM4E 1159/4885 |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | ADORA1 151/4885MAPT 4716/4885KDM4E 3800/4885 |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | METAP1, METAP2, ENPEP | ADORA1 2941/4885MAPT 1551/4885KDM4E 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.